Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET
Company Participants
Helen Rubinstein - Director, IR
Barry Greene - Chief Executive Officer
Kimi Iguchi - Chief Financial Officer
Jim Doherty - Chief Development Officer
Chris Benecchi - Chief Business Officer
Jeff Jonas - Chief Innovation Officer
Conference Call Participants
Yasmeen Rahimi - Piper Sandler
Ritu Baral - Cowen
Salveen Richter - Goldman Sachs
Paul Matteis - Stifel
Laura Chico - Wedbush
Jay Olson - Oppenheimer
Ami Fadia - Needham & Company
Sumant Kulkarni - Canaccord Genuity
Joon Lee - Truist
Operator
Good morning. Welcome to the Sage Therapeutics' Third Quarter 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Sage's website at sagerx.com. This call is the property of Sage Therapeutics and recording, reproduction, or transmission of this call without the expressed written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded. I would now like to introduce Helen Rubinstein, Director of Investor Relations at Sage. Please go ahead.
Helen Rubinstein
Good morning and thank you for joining Sage Therapeutics' third quarter 2022 financial results conference call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at sagerx.com where you can find the press release related to today's call as well as the slides that contain supplemental detail.
I'd like to point out that we will be making forward-looking statements which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please consult the risk factors discussed in today's press release and in our SEC filings for additional detail. We will begin the call with prepared remarks by Barry Greene, our Chief Executive Officer, who will provide an overview of our progress during the third quarter.
We will also be joined by Chris Benecchi, our Chief Business Officer, who will provide an update on our progress and preparation for the potential launch of zuranolone in MDD and PPD, Jim Doherty, our Chief Development Officer will review recent progress and development activities across our programs and Kimi Iguchi, our Chief Financial Officer will review the financial results from the quarter.
With that, I'll now turn the call over to Barry.